Literature DB >> 8978822

Translocation of Src kinase to the cell periphery is mediated by the actin cytoskeleton under the control of the Rho family of small G proteins.

V J Fincham1, M Unlu, V G Brunton, J D Pitts, J A Wyke, M C Frame.   

Abstract

We have isolated Swiss 3T3 subclones that are resistant to the mitogenic and morphological transforming effects of v-Src as a consequence of aberrant translocation of the oncoprotein under low serum conditions. In chicken embryo and NIH 3T3 fibroblasts under similar conditions, v-Src rapidly translocates from the perinuclear region to the focal adhesions upon activation of the tyrosine kinase, resulting in downstream activation of activator protein-1 and mitogen-activated protein kinase, which are required for the mitogenic and transforming activity of the oncoprotein. Since serum deprivation induces cytoskeletal disorganization in Swiss 3T3, we examined whether regulators of the cytoskeleton play a role in the translocation of v-Src, and also c-Src, in response to biological stimuli. Actin stress fibers and translocation of active v-Src to focal adhesions in quiescent Swiss 3T3 cells were restored by microinjection of activated Rho A and by serum. Double labeling with anti-Src and phalloidin demonstrated that v-Src localized along the reformed actin filaments in a pattern that would be consistent with trafficking in complexes along the stress fibers to focal adhesions. Furthermore, treatment with the actin-disrupting drug cytochalasin D, but not the microtubule-disrupting drug nocodazole, prevented v-Src translocation. In addition to v-Src, we observed that PDGF-induced, Rac-mediated membrane ruffling was accompanied by translocation of c-Src from the cytoplasm to the plasma membrane, an effect that was also blocked by cytochalasin D. Thus, we conclude that translocation of Src from its site of synthesis to its site of action at the cell membrane requires an intact cytoskeletal network and that the small G proteins of the Rho family may specify the peripheral localization in focal adhesions or along the membrane, mediated by their effects on the cytoskeleton.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8978822      PMCID: PMC2133963          DOI: 10.1083/jcb.135.6.1551

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  42 in total

1.  Transformation by a temperature sensitive mutant of Rous sarcoma virus in the absence of serum.

Authors:  J G Bell; J A Wyke; I A Macpherson
Journal:  J Gen Virol       Date:  1975-05       Impact factor: 3.891

2.  Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells.

Authors:  S Cowley; H Paterson; P Kemp; C J Marshall
Journal:  Cell       Date:  1994-06-17       Impact factor: 41.582

3.  The protein encoded by the transforming gene of avian sarcoma virus (pp60src) and a homologous protein in normal cells (pp60proto-src) are associated with the plasma membrane.

Authors:  S A Courtneidge; A D Levinson; J M Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  1980-07       Impact factor: 11.205

4.  Size-variant pp60src proteins of recovered avian sarcoma viruses interact with adhesion plaques as peripheral membrane proteins: effects on cell transformation.

Authors:  J G Krueger; E A Garber; S S Chin; H Hanafusa; A R Goldberg
Journal:  Mol Cell Biol       Date:  1984-03       Impact factor: 4.272

5.  Identification of a Rous sarcoma virus transformation-related protein in normal avian and mammalian cells.

Authors:  L R Rohrschneider; R N Eisenman; C R Leitch
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

6.  The use of Rous sarcoma virus transformation mutants with differing tyrosine kinase activities to study the relationships between vinculin phosphorylation, pp60v-src location and adhesion plaque integrity.

Authors:  S Kellie; B Patel; N M Wigglesworth; D R Critchley; J A Wyke
Journal:  Exp Cell Res       Date:  1986-07       Impact factor: 3.905

7.  Localization of the ASV src gene product to the plasma membrane of transformed cells by electron microscopic immunocytochemistry.

Authors:  M C Willingham; G Jay; I Pastan
Journal:  Cell       Date:  1979-09       Impact factor: 41.582

8.  Partial characterization of the mitogenic action of pp60v-src, the oncogenic protein product of the src gene of avian sarcoma virus.

Authors:  J P Durkin; J F Whitfield
Journal:  J Cell Physiol       Date:  1984-08       Impact factor: 6.384

9.  Immunofluorescent localization of the transforming protein of Rous sarcoma virus with antibodies against a synthetic src peptide.

Authors:  E A Nigg; B M Sefton; T Hunter; G Walter; S J Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

10.  Association of the src gene product of Rous sarcoma virus with cytoskeletal structures of chicken embryo fibroblasts.

Authors:  J G Burr; G Dreyfuss; S Penman; J M Buchanan
Journal:  Proc Natl Acad Sci U S A       Date:  1980-06       Impact factor: 11.205

View more
  58 in total

1.  Inhibition of the motility and growth of B16F10 mouse melanoma cells by dominant negative mutants of Dok-1.

Authors:  T Hosooka; T Noguchi; H Nagai; T Horikawa; T Matozaki; M Ichihashi; M Kasuga
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

2.  The SH3 domain directs acto-myosin-dependent targeting of v-Src to focal adhesions via phosphatidylinositol 3-kinase.

Authors:  V J Fincham; V G Brunton; M C Frame
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

3.  Phosphorylation of Trask by Src kinases inhibits integrin clustering and functions in exclusion with focal adhesion signaling.

Authors:  Danislav S Spassov; Ching Hang Wong; Natalia Sergina; Deepika Ahuja; Michael Fried; Dean Sheppard; Mark M Moasser
Journal:  Mol Cell Biol       Date:  2010-12-28       Impact factor: 4.272

4.  The catalytic activity of the Src family kinases is required to disrupt cadherin-dependent cell-cell contacts.

Authors:  D W Owens; G W McLean; A W Wyke; C Paraskeva; E K Parkinson; M C Frame; V G Brunton
Journal:  Mol Biol Cell       Date:  2000-01       Impact factor: 4.138

5.  Association of mouse actin-binding protein 1 (mAbp1/SH3P7), an Src kinase target, with dynamic regions of the cortical actin cytoskeleton in response to Rac1 activation.

Authors:  M M Kessels; A E Engqvist-Goldstein; D G Drubin
Journal:  Mol Biol Cell       Date:  2000-01       Impact factor: 4.138

6.  The Rho-mDia1 pathway regulates cell polarity and focal adhesion turnover in migrating cells through mobilizing Apc and c-Src.

Authors:  Norikazu Yamana; Yoshiki Arakawa; Tomohiro Nishino; Kazuo Kurokawa; Masahiro Tanji; Reina E Itoh; James Monypenny; Toshimasa Ishizaki; Haruhiko Bito; Kazuhiko Nozaki; Nobuo Hashimoto; Michiyuki Matsuda; Shuh Narumiya
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

7.  Central role of protein kinase Cepsilon in constitutive activation of ERK1/2 and Rac1 in the malignant cells of hairy cell leukemia.

Authors:  Joseph R Slupsky; Aura S Kamiguti; Robert J Harris; John C Cawley; Mirko Zuzel
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

8.  Determination of hierarchical relationship of Src and Rac at subcellular locations with FRET biosensors.

Authors:  Mingxing Ouyang; Jie Sun; Shu Chien; Yingxiao Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-17       Impact factor: 11.205

9.  Visualization of Src activity at different compartments of the plasma membrane by FRET imaging.

Authors:  Jihye Seong; Shaoying Lu; Mingxing Ouyang; He Huang; Jin Zhang; Margaret C Frame; Yingxiao Wang
Journal:  Chem Biol       Date:  2009-01-30

10.  eNOS-derived nitric oxide regulates endothelial barrier function through VE-cadherin and Rho GTPases.

Authors:  Annarita Di Lorenzo; Michelle I Lin; Takahisa Murata; Shira Landskroner-Eiger; Michael Schleicher; Milankumar Kothiya; Yasuko Iwakiri; Jun Yu; Paul L Huang; William C Sessa
Journal:  J Cell Sci       Date:  2013-09-17       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.